Legochem Biosciences contracted technology transfer of antibiotic to AstraZeneca

Published: 2014-01-17 06:57:00

Updated: 2014-01-17 06:57:00

(Yakup Shinmoon)

On Jan 14, Legochem Biosciences announced that they made a contract of 'Gram-negative antibiotic (LCB10-0200) candidate substance' technology transfer to AstraZeneca.

According to the company, the contract includes technology transfer of right to use 'LCB10-0200' for monotherapy adding the existing combination therapy contract, and the contract price is 14.791 billion ...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.